VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadju...

Descripción completa

Detalles Bibliográficos
Autores principales: Smyth, Elizabeth, Knödler, Maren, Giraut, Anne, Mauer, Murielle, Nilsson, Magnus, Van Grieken, Nicole, Wagner, Anna Dorothea, Moehler, Markus, Lordick, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002471/
https://www.ncbi.nlm.nih.gov/pubmed/32083013
http://dx.doi.org/10.3389/fonc.2019.01320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002471/
https://www.ncbi.nlm.nih.gov/pubmed/32083013
http://dx.doi.org/10.3389/fonc.2019.01320

Ejemplares similares